Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016766245> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3016766245 abstract "Background and importance The acquisition of resistance by bacteria has meant that new antimicrobials appear. Ceftazidime–avibactam is a restricted antibiotic that is used in multiresistant infections that put the patient‘s life at risk. Aim and objectives To evaluate the effectiveness of ceftazidime–avibactam as a treatment for multidrug resistant infections in a third level hospital. Material and methods This was a before and after study in patients with multidrug resistant infections treated with ceftazidime–avibactam between April 2018 and April 2019. Those The main variable of our study was C reactive protein (CRP) before and after treatment. Secondary variables included age, sex, weight, dosage and isolated microorganism. An initial descriptive analysis was performed with mean (SD) or median (IQR, P25–P75) for numerical variables or absolute frequencies for nominal variables. For statistical analysis, the Wilcoxon test of paired measures was used to determine if there were differences in median CRP values before and after antibiotic treatment. The analyses were performed using the SPSS/PC statistical programme (V.24.0 for Windows, SPSS Inc, Chicago, Illinois, USA). Results Thirty-six patients were treated with ceftazidime–avibactam from April 2018 to April 2019, of whom 32 were studied. Of these, 21 were men, average age was 63±11 years and average weight was 71±20 kg. The most common dosage was 2 g every 8 hours (25) and the most prevalent microorganism was Klebsiella pneumoniae (25). The median initial CRP was 8.85 mg/dL (1.53–17.27) while the median final CRP was 3.29 mg/dL (0.59–6.78). Statistically significant differences were found in median CRP before and after antibiotic treatment (z=−3.35; p=0.001). Conclusion and relevance Ceftazidime–avibactam was found to be effective in patients presenting with multidrug resistant infections as it significantly reduced CRP, a marker used to monitor infections. References and/or acknowledgements No conflict of interest." @default.
- W3016766245 created "2020-04-24" @default.
- W3016766245 creator A5026232945 @default.
- W3016766245 creator A5033055030 @default.
- W3016766245 creator A5057292633 @default.
- W3016766245 creator A5064760489 @default.
- W3016766245 creator A5073754705 @default.
- W3016766245 creator A5077340279 @default.
- W3016766245 creator A5084973058 @default.
- W3016766245 date "2020-03-01" @default.
- W3016766245 modified "2023-09-23" @default.
- W3016766245 title "5PSQ-023 Effectiveness of ceftazidime–avibactam in infections by multiresistant microorganisms" @default.
- W3016766245 doi "https://doi.org/10.1136/ejhpharm-2020-eahpconf.340" @default.
- W3016766245 hasPublicationYear "2020" @default.
- W3016766245 type Work @default.
- W3016766245 sameAs 3016766245 @default.
- W3016766245 citedByCount "0" @default.
- W3016766245 crossrefType "proceedings-article" @default.
- W3016766245 hasAuthorship W3016766245A5026232945 @default.
- W3016766245 hasAuthorship W3016766245A5033055030 @default.
- W3016766245 hasAuthorship W3016766245A5057292633 @default.
- W3016766245 hasAuthorship W3016766245A5064760489 @default.
- W3016766245 hasAuthorship W3016766245A5073754705 @default.
- W3016766245 hasAuthorship W3016766245A5077340279 @default.
- W3016766245 hasAuthorship W3016766245A5084973058 @default.
- W3016766245 hasBestOaLocation W30167662451 @default.
- W3016766245 hasConcept C104317684 @default.
- W3016766245 hasConcept C126322002 @default.
- W3016766245 hasConcept C141071460 @default.
- W3016766245 hasConcept C2775933652 @default.
- W3016766245 hasConcept C2776968632 @default.
- W3016766245 hasConcept C2777058267 @default.
- W3016766245 hasConcept C2777406300 @default.
- W3016766245 hasConcept C2777637488 @default.
- W3016766245 hasConcept C501593827 @default.
- W3016766245 hasConcept C523546767 @default.
- W3016766245 hasConcept C54355233 @default.
- W3016766245 hasConcept C547475151 @default.
- W3016766245 hasConcept C55493867 @default.
- W3016766245 hasConcept C71924100 @default.
- W3016766245 hasConcept C86803240 @default.
- W3016766245 hasConcept C89423630 @default.
- W3016766245 hasConceptScore W3016766245C104317684 @default.
- W3016766245 hasConceptScore W3016766245C126322002 @default.
- W3016766245 hasConceptScore W3016766245C141071460 @default.
- W3016766245 hasConceptScore W3016766245C2775933652 @default.
- W3016766245 hasConceptScore W3016766245C2776968632 @default.
- W3016766245 hasConceptScore W3016766245C2777058267 @default.
- W3016766245 hasConceptScore W3016766245C2777406300 @default.
- W3016766245 hasConceptScore W3016766245C2777637488 @default.
- W3016766245 hasConceptScore W3016766245C501593827 @default.
- W3016766245 hasConceptScore W3016766245C523546767 @default.
- W3016766245 hasConceptScore W3016766245C54355233 @default.
- W3016766245 hasConceptScore W3016766245C547475151 @default.
- W3016766245 hasConceptScore W3016766245C55493867 @default.
- W3016766245 hasConceptScore W3016766245C71924100 @default.
- W3016766245 hasConceptScore W3016766245C86803240 @default.
- W3016766245 hasConceptScore W3016766245C89423630 @default.
- W3016766245 hasLocation W30167662451 @default.
- W3016766245 hasOpenAccess W3016766245 @default.
- W3016766245 hasPrimaryLocation W30167662451 @default.
- W3016766245 hasRelatedWork W1216796 @default.
- W3016766245 hasRelatedWork W13143853 @default.
- W3016766245 hasRelatedWork W13584953 @default.
- W3016766245 hasRelatedWork W16503382 @default.
- W3016766245 hasRelatedWork W17740964 @default.
- W3016766245 hasRelatedWork W18485121 @default.
- W3016766245 hasRelatedWork W345745 @default.
- W3016766245 hasRelatedWork W4768966 @default.
- W3016766245 hasRelatedWork W5480534 @default.
- W3016766245 hasRelatedWork W19473011 @default.
- W3016766245 isParatext "false" @default.
- W3016766245 isRetracted "false" @default.
- W3016766245 magId "3016766245" @default.
- W3016766245 workType "article" @default.